 | |
| How to Break Resistance to Anti-EGFR Treatment in Head & Neck Cancer. Lillian L. Siu. June 3rd, 12:45 p.m. |
| |
| |
| START: phase III study of L-BLP25 cancer immunotherapy for unresectable stage III NSCLC. Charles Butts |
| |
| |
| will be on location at - Register to receive daily video updates from trial authors! |
| |
| |
| RCTs examining CS versus IS of delivering systemic treatment for untreated mCRC. Scott Berry |
| |
| |
| PMCC IMPACT using genotyping and targeted NGS. Philippe Bedard |
| |
| |
| Double Blind Randomized trial of aflibercept versus placebo with docetaxel and prednisone. Ian Tannock |
| |
| |
| Abstract #1551 Risk of hospital-related morbidity among survivors of breast cancer in BC. Christine Simmons |
| |
| |
| Register now for Best of ASCO® Canada. View the agenda for more details. |
| |
| |
| Meet at , booth 2080! Sign up to our newsletter to receive daily video updates during June 1-3! |
| |
| |
| New Medical Oncologist job opportunity in Newfoundland. Visit our website to view this and other opportunities. |
| |
| |
| Join us in Chicago for the ASCO Annual Meeting at Booth 2080 to learn more about ! |
| |
| |
| My Patient Does Not Have a Targetable Mutation. June 1st, 3:00 p.m, Frances Shepherd. |
| |
| |
| Randomized phase II study of OGX-427 in men with mCRPC and PSA progression while receiving AA. Kim Chi. |
| |
| |
| Androgen Deprivation Therapy for RPC: Intermittent or Continuous Blockade. June 3rd, 5:05 p.m. Kim Chi. |
| |
| |
| A prognostic model for predicting OS in pts with mCRPC treated with AA after docetaxel. Kim Chi. |
| |
| |
| Vinblastine in chemo-naive children with unresectable or progressive low grade glioma. Eric Bouffet. |
| |
| |
| Study to optimize and standardize ALK IHC and FISH for ALKgene rearrangements. Dr. Tsao. |
| |
| |
| Applying the Results from Recent Clinical Trials into Daily Practice. Stephen Chia. June 2nd, 5:05 p.m. |
| |
| |
| Anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2+ MBC. Dr. Chia. |
| |
| |
| Sunitinib given on an individualized schedule as 1st-line therapy for MRCC. Dr. Bjarnason. |
| |
